Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does TOCILIZUMAB Cause Obstructive airways disorder? 15 Reports in FDA Database

Grow Your Own Natural Pharmacy at Home

Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.

Get the Kit

According to the FDA Adverse Event Reporting System (FAERS), 15 reports of Obstructive airways disorder have been filed in association with TOCILIZUMAB (Tocilizumab-anoh). This represents 0.0% of all adverse event reports for TOCILIZUMAB.

15
Reports of Obstructive airways disorder with TOCILIZUMAB
0.0%
of all TOCILIZUMAB reports
6
Deaths
4
Hospitalizations

How Dangerous Is Obstructive airways disorder From TOCILIZUMAB?

Of the 15 reports, 6 (40.0%) resulted in death, 4 (26.7%) required hospitalization, and 3 (20.0%) were considered life-threatening.

Is Obstructive airways disorder Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for TOCILIZUMAB. However, 15 reports have been filed with the FAERS database.

What Other Side Effects Does TOCILIZUMAB Cause?

Drug ineffective (32,342) Rheumatoid arthritis (20,652) Pain (18,384) Off label use (18,256) Arthralgia (15,536) Joint swelling (14,831) Fatigue (13,802) Rash (12,327) Drug intolerance (11,952) Contraindicated product administered (11,547)

What Other Drugs Cause Obstructive airways disorder?

ALBUTEROL (4,195) TIOTROPIUM (2,634) PREDNISONE (2,480) BUDESONIDE\FORMOTEROL (2,210) MONTELUKAST (2,073) MEPOLIZUMAB (1,883) OMALIZUMAB (1,670) CICLESONIDE (1,403) FLUTICASONE\SALMETEROL (1,253) BUDESONIDE (1,214)

Which TOCILIZUMAB Alternatives Have Lower Obstructive airways disorder Risk?

TOCILIZUMAB vs TOCILIZUMAB-AAZG TOCILIZUMAB vs TOCOPHEROL TOCILIZUMAB vs TOFACITINIB TOCILIZUMAB vs TOFERSEN TOCILIZUMAB vs TOLNAFTATE

Related Pages

TOCILIZUMAB Full Profile All Obstructive airways disorder Reports All Drugs Causing Obstructive airways disorder TOCILIZUMAB Demographics